Solid Dosage and Excipients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Solid Dosage and Excipients


PharmTech Solid Dosage and Excipients

Pharmaceutical Technology’s Solid Dosage and Excipients e-book examines emerging trends in the formulation and manufacture of solid dosage drugs, as well as the role of excipients in enhancing the functionality of these drug forms. This e-book format includes videos, interactive functionality, and links to additional resources.

--The editors of Pharmaceutical Technology

View Pharmaceutical Technology's Solid Dosage and Excipients eBook


Controlled Release

Controlled Release
Controlled-Release Technologies Create Opportunities for Solid-Dosage Drug Formulators
Lifecycle management opportunities including clinical and compliance benefits coupled with the need for patent extensions are impacting the development of controlled-release technologies for solid-dosage drugs.

by Cynthia A. Challener


Generic-Drug Formulation

Generic-Drug Formulations
Selection of Excipients in Generic Formulations
The selection of excipients is important in generic formulations due to the impact it has on the risk and performance of generic drugs.

by Aloka Srinivasan, Paraxel International


Hot-Melt Extrusion

Hot-Melt Extrusion
A Practical Guide to Hot-Melt Extrusion Scale-Up for Pharmaceutical Applications
The author discusses various aspects of the hot-melt extrusion process and outlines a practical approach to scale-up.

by Justin R. Hughey, Hovione


Video Interview
Advances in Hot-Melt Extrusion Manufacturing

An interview with Charlie Martin, Leistritz Extrusion


Solid Dose Drug Design

Product Design
Safety by Design—Mitigating the Risk of Medication Errors Through Product Design
The increasing prevalence and high cost of medication errors have prompted regulators and manufacturers to look into the role of product design in ensuring the safe and correct use of medicines. Experts share insights on how product appearance such as size, shape, color, and imprint can make a difference in reducing medication errors.

An Interview with Kamlesh Oza and Perry Cozzone, Colorcon


Modular Systems

Modular Systems
Using Modular Systems in Solid-Dosage Manufacturing
Modular systems offer a more efficient way to design and build manufacturing facilities. Although recent focus in the pharmaceutical industry has been on using modular systems in biopharmaceutical processing, the same advantages can be applied to small-molecule API and solid-dosage product manufacturing. The authors describe how modular systems can be applied to continuous solid-dosage and nutraceutical manufacturing.

by Pär Almhem, Reiner Lemperle, and Camilla Sivertsson; ModWave


Video Interview
Continuous Manufacturing for Solid-Dosage Drug Production

An interview with Doug Hausner, Engineering Research Center for Structured Organic Particulate Systems, Rutgers University



Granluation

Granulation
Obtaining User-Defined Particle Size Distribution Using Dry Granulation
Users can define a desired particle-size distribution using continuous dry granulation. The author examines the effect of compaction force, gap width, and sieve setup on granule size.

by Dejan Djuric, L.B. Bohle



Quality by Design

Quality by Design
A Quality-by-Design Approach to Optimize In-Process Curing of EUDRAGIT NM 30 D
Previous studies with EUDRAGIT NM 30 D showed that storage stability can be achieved with in-process curing at specific conditions. The aim of this study was to identify and investigate the influence and correlation of critical process parameters for the optimization of in-process curing.

by Thomas Dassinger, Jessica Müller-Albers, and Sascha Jautze; Evonik Industries



 

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics

Click here